Showing 221-230 of 501 results for "".
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- Martine Williamson Named Revlon’s New Chief Marketing Officerhttps://modernaesthetics.com/news/martine-williamson-named-revlons-new-chief-marketing-officer/2473025/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join
- Lizette Williams, Global Head of Vertical Solutions Marketing at Facebook, Joins RealSelf’s Boardhttps://modernaesthetics.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board-1/2472996/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberl
- Amber Edwards Named Alastin Skincare’s New Chief Commercial Officerhttps://modernaesthetics.com/news/amber-edwards-named-alastin-skincares-new-chief-commercial-officer/2472971/Amber Edwards is Alastin Skincare’s new Chief Commercial Officer, effective July 31, 2020 Ms. Edwards most recently served as President of North America for Sinclair Pharma. Prior to Sinclair, she was at Allergan, Inc. where she was the Vice President of International S
- Aaron Burton Named CEO at Scitonhttps://modernaesthetics.com/news/aaron-burton-named-ceo-at-sciton/2472888/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently o
- BTL Suit Alleges False Advertising by Allerganhttps://modernaesthetics.com/news/btl-suit-alleges-false-advertising-by-allergan-1/2472885/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- FDA Says No to Evolus' Botox Rivalhttps://modernaesthetics.com/news/fda-says-no-to-evolus-botox-rival/2472089/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more